A systematic review and meta-analysis finds that weight-loss interventions are associated with decreased psoriasis severity ...

A large US claims analysis links out-of-pocket medication costs with adherence and discontinuation patterns among patients ...

Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to ...

And the most recent article came out of JAMA in 2024, and they found that for every 1 g increase in urinary sodium, you ...

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

Immune-mediated diseases specialist Alumis has announced positive top-line results from its Phase III ONWARD1 and ONWARD2 ...

Oruka analysis: ultra-durable psoriasis biologics ORKA-001/002 aim for 1–3 doses/yr with strong efficacy; liquid balance ...

Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh ...

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.